@book{:/content/books/9789210046527,
  title = {Contraceptive Use by Method 2019},
  author = {Unies, Nations},
  date = {2019},
  publisher = {{United Nations}},
  url = {https://www.un-ilibrary.org/content/books/9789210046527},
  urldate = {2023-05-08},
  abstract = {This data booklet highlights estimates of the prevalence of individual contraceptive methods based on the World Contraceptive Use 2019 (which draws from 1,247 surveys for 195 countries or areas of the world) and additional tabulations obtained from microdata sets and survey reports. The estimates are presented for female and male sterilisation, intrauterine device (IUD), implant, injectable, pill, male condom, withdrawal, rhythm and other methods combined.}
}

@video{1980HommeVient,
  entrysubtype = {tvbroadcast},
  title = {1980 : un homme vient à la télé dire qu'il prend la pilule | INA},
  shorttitle = {1980},
  booktitle = {ina.fr},
  url = {https://www.ina.fr/ina-eclaire-actu/1980-pilule-homme-contraception-masculine},
  urldate = {2023-06-04},
  abstract = {Où en est-on de la contraception masculine ? Le journal «Libération» a demandé mardi 23 août aux pouvoir publics et aux laboratoires de développer de «vraies solutions». Il y a plus de 40 ans, des hommes testaient déjà une pilule. Pierre Colin était l'un d'eux et parlait à la télévision en 1980. Il revient sur ce moment clé.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\HEIDITX9\\1980-pilule-homme-contraception-masculine.html}
}

@article{abbeMaleContraception2020,
  title = {Male {{Contraception}}},
  author = {Abbe, Carmen R. and Page, Stephanie T. and Thirumalai, Arthi},
  date = {2020-09-30},
  journaltitle = {The Yale Journal of Biology and Medicine},
  shortjournal = {Yale J Biol Med},
  volume = {93},
  number = {4},
  eprint = {33005125},
  eprinttype = {pmid},
  pages = {603--613},
  issn = {0044-0086},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513428/},
  urldate = {2023-03-15},
  abstract = {Unintended pregnancy is a global public health problem. Despite a variety of female contraceptive options, male contraceptive options are limited to the condom and vasectomy. Condoms have high failure rates and surgical vasectomy is not reliably reversible. There is a global need and desire for novel male contraceptive methods. Hormonal methods have progressed the furthest in clinical development and androgen plus progestin formulations hold promise as a marketable, reversible male contraceptive over the next decade. Investigators have tested androgen plus progestin approaches using oral, transdermal, subdermal, and injectable drug formulations and demonstrated the short-term safety and reversibility of hormonal male contraception. The most commonly reported side effects associated with hormonal male contraception include weight gain, acne, slight suppression of serum high-density cholesterol, mood changes, and changes in libido. Efficacy trials of hormonal male contraceptives have demonstrated contraceptive efficacy rates greater than that of condoms. Although there has been less progression in the development of nonhormonal male contraceptives, potentially reversible vaso-occlusive methods are currently in clinical trials in some countries. Various studies have confirmed both men and women’s desire for novel male contraceptives. Barriers to development include an absence of investment from pharmaceutical companies, concerns regarding side effects and spermatogenic rebound with hormonal methods, and lack of clear reversibility and proven effectiveness of nonhormonal methods. The ultimate availability of male contraceptives could have an important impact on decreasing global unintended pregnancy rates (currently 40\% of all pregnancies) and will be a step towards reproductive justice and greater equity in family planning.},
  pmcid = {PMC7513428},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\993XSE8J\\Abbe et al. - 2020 - Male Contraception.pdf}
}

@online{ActualiteAnneauContraceptif,
  title = {Actualité - Anneau contraceptif masculin Andro-switch : il faut démontrer l’efficacité et la sécurité du dispositif},
  shorttitle = {Actualité - Anneau contraceptif masculin Andro-switch},
  url = {https://ansm.sante.fr/actualites/anneau-contraceptif-masculin-andro-switch-il-faut-demontrer-lefficacite-et-la-securite-du-dispositif-1},
  urldate = {2023-05-18},
  abstract = {Anneau contraceptif masculin Andro-switch : il faut démontrer l’efficacité et la sécurité du dispositif sur le site de l'Agence nationale de sécurité du médicamentet des produits de santé},
  langid = {french},
  organization = {{ANSM}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\ATJZ3HTH\\anneau-contraceptif-masculin-andro-switch-il-faut-demontrer-lefficacite-et-la-securite-du-dispo.html}
}

@misc{albrechtQuelleEstPlace2023,
  title = {Quelle est la place de la pilule contraceptive en France et dans le monde ?},
  author = {ALBRECHT},
  date = {2023},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\U7PGX69P\\Elise - Quelle est la place de la pilule contraceptive en .pdf}
}

@article{AlertePilule2012,
  entrysubtype = {newspaper},
  title = {Alerte sur la pilule},
  date = {2012-12-17},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/a-la-une/article/2012/12/17/alerte-sur-la-pilule_1806558_3208.html},
  urldate = {2023-05-21},
  abstract = {Le Monde.fr - 1er site d’information sur l’actualité. Retrouvez ici une info de la thématique A la une du 17 décembre 2012 sur le sujet Alerte sur la pilule},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\8P6D69DL\\alerte-sur-la-pilule_1806558_3208.html}
}

@book{anne-sophiedelcourHommeSousPilule,
  title = {L'homme sous pilule},
  author = {{Anne-Sophie Delcour} and {Lucymacaroni}},
  publisher = {{MARAbulles}},
  isbn = {978-2-501-14694-4},
  langid = {french},
  pagetotal = {175}
}

@software{anshJiffyReader2023,
  title = {Jiffy {{Reader}}},
  author = {Ansh},
  date = {2023-05-23T21:04:42Z},
  origdate = {2022-05-20T18:20:29Z},
  url = {https://github.com/ansh/jiffyreader.com},
  urldate = {2023-05-24},
  abstract = {A Browser Extension for faster reading on ANY website!},
  keywords = {bionic,bionic-reading,bookmark,brave-extension,browser-extension,chrome-extension,firefox-extension,opera-extension,reading,safari-extension,web-extension}
}

@misc{associationfrancaisedurologieVasectomieContraceptive2012,
  title = {Vasectomie Contraceptive},
  author = {{Association Française d'Urologie}},
  date = {2012-05},
  url = {https://www.urofrance.org/sites/default/files/vasectomie_1.pdf},
  urldate = {2023-05-01},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\T8R8SBB5\\vasectomie_1.pdf}
}

@article{balbachOndemandMaleContraception2023,
  title = {On-Demand Male Contraception via Acute Inhibition of Soluble Adenylyl Cyclase},
  author = {Balbach, Melanie and Rossetti, Thomas and Ferreira, Jacob and Ghanem, Lubna and Ritagliati, Carla and Myers, Robert W. and Huggins, David J. and Steegborn, Clemens and Miranda, Ileana C. and Meinke, Peter T. and Buck, Jochen and Levin, Lonny R.},
  date = {2023-02-14},
  journaltitle = {Nature Communications},
  shortjournal = {Nat Commun},
  volume = {14},
  number = {1},
  pages = {637},
  issn = {2041-1723},
  doi = {10.1038/s41467-023-36119-6},
  url = {https://www.nature.com/articles/s41467-023-36119-6},
  urldate = {2023-05-15},
  abstract = {Abstract             Nearly half of all pregnancies are unintended; thus, existing family planning options are inadequate. For men, the only choices are condoms and vasectomy, and most current efforts to develop new contraceptives for men impact sperm development, meaning that contraception requires months of continuous pretreatment. Here, we provide proof-of-concept for an innovative strategy for on-demand contraception, where a man would take a birth control pill shortly before sex, only as needed. Soluble adenylyl cyclase (sAC) is essential for sperm motility and maturation. We show a single dose of a safe, acutely-acting sAC inhibitor with long residence time renders male mice temporarily infertile. Mice exhibit normal mating behavior, and full fertility returns the next day. These studies define sAC inhibitors as leads for on-demand contraceptives for men, and they provide in vivo proof-of-concept for previously untested paradigms in contraception; on-demand contraception after just a single dose and pharmacological contraception for men.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KMK2FY5T\\Balbach et al. - 2023 - On-demand male contraception via acute inhibition .pdf}
}

@article{beatriceContraceptifMasculinEfficace1996,
  title = {Contraceptif masculin: efficace mais douloureux 401 couples ont testé, avec un taux de réussite de 98,6\%, cette piqûre hebdomadaire.},
  shorttitle = {Contraceptif masculin},
  author = {family=Béatrice, given=BANTMAN, given-i=BANTMAN},
  date = {1996-04-03},
  journaltitle = {Libération},
  pages = {22},
  url = {https://nouveau.europresse.com/Link/BUCOMPIEGNET_2/news%C2%B719960403%C2%B7LI%C2%B749487},
  abstract = {Ce n'est pas encore la pilule pour hommes mais la piqûre  masculine. L'Organisation mondiale de la santé (OMS) annonce une "avancée majeure dans la mise au point d'une nouvelle ...},
  langid = {FRA},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\4PA5KGTT\\0.html}
}

@book{bobikaCoeurZobs2022,
  title = {Le Coeur Des Zobs},
  author = {{Bobika}},
  date = {2022-09},
  series = {Mâtin!},
  edition = {Dargaud},
  isbn = {978-2-205-20374-5},
  pagetotal = {144}
}

@online{CesHommesQui,
  title = {Ces Hommes Qui Ont Choisi La Vasectomie~: «~{{Notre}} Sexualité Est plus Spontanée et plus Sereine~»},
  url = {https://www.lemonde.fr/parentalite/article/2023/04/10/ces-hommes-qui-ont-choisi-la-vasectomie-notre-sexualite-est-plus-spontanee-et-plus-sereine_6168906_6145697.html},
  urldate = {2023-05-20},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\SULQ4N7U\\ces-hommes-qui-ont-choisi-la-vasectomie-notre-sexualite-est-plus-spontanee-et-plus-sereine_6168.html}
}

@article{CesHommesQui2023,
  entrysubtype = {newspaper},
  title = {Ces hommes qui ont choisi la vasectomie : « Notre sexualité est plus spontanée et plus sereine »},
  shorttitle = {Ces hommes qui ont choisi la vasectomie},
  date = {2023-04-10},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/parentalite/article/2023/04/10/ces-hommes-qui-ont-choisi-la-vasectomie-notre-sexualite-est-plus-spontanee-et-plus-sereine_6168906_6145697.html},
  urldate = {2023-04-11},
  abstract = {Cette méthode de stérilisation masculine reste marginale en France, bien qu’en hausse. Répartition de la charge contraceptive, refus de procréer dans un monde troublé… Les motivations sont diverses, et les regrets peu nombreux.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\83FESL9D\\ces-hommes-qui-ont-choisi-la-vasectomie-notre-sexualite-est-plus-spontanee-et-plus-sereine_6168.html}
}

@inreference{CoitInterrompu2022,
  title = {Coït interrompu},
  booktitle = {Wikipédia},
  date = {2022-06-21T07:38:46Z},
  url = {https://fr.wikipedia.org/w/index.php?title=Co%C3%AFt_interrompu&oldid=194713871},
  urldate = {2023-05-01},
  abstract = {Le coït interrompu (coitus interruptus en latin) ou méthode du retrait est une pratique sexuelle et un moyen de contraception qui consiste à interrompre le rapport sexuel vaginal juste avant l'éjaculation. L'homme retire à ce moment son pénis du vagin et l'éjaculation a alors lieu en dehors de celui-ci, évitant ainsi la fécondation. La méthode du retrait fait partie des méthodes naturelles de régulation des naissances. Bien qu'ancienne, la méthode du retrait a été largement popularisée dans les films pornographiques à partir des années 1980. En effet, à l'écran une éjaculation hors du vagin rend davantage visible cette éjaculation tout en se passant du préservatif (Débat sur l'utilisation du préservatif dans l'industrie du film pornographique). Cette méthode de contraception a néanmoins une efficacité beaucoup plus faible que les méthodes plus classiques. Elle ne protège en outre pas des infections sexuellement transmissibles. La méthode du retrait ne doit pas être confondue avec le contrôle de l'orgasme (ou edging) qui est une technique d'intensification du plaisir sexuel ni avec le déni d'orgasme qui relève des pratiques BDSM.},
  langid = {french},
  annotation = {Page Version ID: 194713871},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\P4RNRTKT\\Coït_interrompu.html}
}

@online{CoitInterrompuWikipedia,
  title = {Coït Interrompu — {{Wikipédia}}},
  url = {https://fr.wikipedia.org/wiki/Co%C3%AFt_interrompu?oldformat=true},
  urldate = {2023-05-01},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KIERFDXZ\\Coït_interrompu.html}
}

@online{ContraceptionChezHomme2019,
  title = {Contraception chez l’homme},
  date = {2019-09},
  url = {https://www.has-sante.fr/jcms/c_1757909/fr/contraception-chez-l-homme},
  urldate = {2023-02-22},
  abstract = {Cette fiche mémo, fondée sur les recommandations les plus récentes, fait partie d’un ensemble de fiches mémo concernant la contraception et complète plusieurs documents sur ce thème produits par la HAS. Elle est un outil pour le professionnel de santé afin de mieux aider les femmes/les hommes à trouver la méthode de contraception qui leur convient le mieux à une période donnée de leur vie.},
  langid = {french},
  organization = {{Haute Autorité de Santé}},
  keywords = {HAS,masculin,officiel},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\PQ56WL3J\\contraception-chez-l-homme.html}
}

@online{ContraceptionCoupleINA,
  title = {Contraception : Couple | INA},
  shorttitle = {Contraception},
  url = {https://www.ina.fr/ina-eclaire-actu/publicite/pub1447446110/contraception-couple},
  urldate = {2023-06-05},
  langid = {french},
  organization = {{ina.fr}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\AAPQENGM\\contraception-couple.html}
}

@online{ContraceptionDefileINA,
  title = {Contraception : Le défilé | INA},
  shorttitle = {Contraception},
  url = {https://www.ina.fr/ina-eclaire-actu/publicite/pub3250603001/contraception-le-defile},
  urldate = {2023-06-05},
  langid = {french},
  organization = {{ina.fr}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KAWZJLXK\\contraception-le-defile.html}
}

@online{ContraceptionHormonaleMasculine2016,
  title = {Contraception hormonale masculine : des résultats prometteurs},
  shorttitle = {Contraception hormonale masculine},
  date = {2016-11-02T18:05:05+01:00},
  url = {https://sante.lefigaro.fr/article/contraception-hormonale-masculine-des-resultats-prometteurs/},
  urldate = {2023-05-08},
  abstract = {Une méthode de contraception par injection d’hormones s’est révélée efficace pour 96\% des volontaires d’un essai commandé par l’OMS.},
  langid = {ISO639-2 fre},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\SHVTMIPC\\contraception-hormonale-masculine-des-resultats-prometteurs.html}
}

@online{ContraceptionJeuneFemme,
  title = {Contraception : Jeune femme | INA},
  shorttitle = {Contraception},
  url = {https://www.ina.fr/ina-eclaire-actu/publicite/pub1447446109/contraception-jeune-femme},
  urldate = {2023-06-05},
  langid = {french},
  organization = {{ina.fr}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\8MHCHEYX\\contraception-jeune-femme.html}
}

@online{ContraceptionJeuneFille,
  title = {Contraception : Jeune fille | INA},
  shorttitle = {Contraception},
  url = {https://www.ina.fr/ina-eclaire-actu/publicite/pub1447446108/contraception-jeune-fille},
  urldate = {2023-06-05},
  langid = {french},
  organization = {{ina.fr}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\SSAVG7WS\\contraception-jeune-fille.html}
}

@online{ContraceptionMasculine,
  title = {La Contraception Masculine},
  url = {https://questionsexualite.fr/choisir-sa-contraception/ma-contraception-et-moi/contraception-masculine-comment-ca-marche},
  urldate = {2023-03-02},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\9ERTACE7\\contraception-masculine-comment-ca-marche.html}
}

@article{ContraceptionMasculineArretez2022,
  title = {contraception masculine arrêtez de vous dorer la pilule !},
  date = {2022-08-23},
  journaltitle = {Libération},
  pages = {1},
  url = {https://nouveau.europresse.com/Link/BUCOMPIEGNET_2/news%C2%B720220823%C2%B7LI%C2%B7181143014},
  abstract = {Appel Libération» demande aux pouvoirs publics et aux laboratoires de développer de vraies solutions pour que la  contraception soit autant une affaire d'hommes que de femmes. pages 2-5  ...},
  langid = {FRA},
  annotation = {Context Object: ctx\_ver=Z39.88-2004\&rft\_val\_fmt=info\%3Aofi\%2Ffmt\%3Akev\%3Amtx\%3Ajournal\&rft.genre=article\&rft.atitle=contraception\%20masculine\%20arr\%c3\%aatez\%20de\%20vous\%20dorer\%20la\%20pilule\%20!\&rft.jtitle=Lib\%c3\%a9ration\&rft.title=Lib\%c3\%a9ration\&rft.description=Appel\%20Lib\%c3\%a9ration\%c2\%bb\%20demande\%20aux\%20pouvoirs\%20publics\%20et\%20aux\%20laboratoires\%20de\%20d\%c3\%a9velopper\%20de\%20vraies\%20solutions\%20pour\%20que\%20la\%20\%20contraception\%20soit\%20autant\%20une\%20affaire\%20d\%27hommes\%20que\%20de\%20femmes.\%20pages\%202-5\%20\%20...\&rft.date=2022-08-23\&rft.language=FRA\&rft.spage=1\&rft.epage=1\&rft\_id=https://nouveau.europresse.com/Link/BUCOMPIEGNET\_2/news\%c2\%b720220823\%c2\%b7LI\%c2\%b7181143014},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KQFWN8YR\\6.html}
}

@article{ContraceptionMasculineAucune2021,
  entrysubtype = {newspaper},
  title = {Contraception masculine : « Il n’y a aucune raison pour que cette charge repose uniquement sur ma copine »},
  shorttitle = {Contraception masculine},
  date = {2021-11-27},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/societe/article/2021/11/27/contraception-masculine-il-n-y-a-aucune-raison-pour-que-cette-charge-repose-uniquement-sur-ma-copine_6103823_3224.html},
  urldate = {2023-05-18},
  abstract = {Sous-vêtements chauffants, injections de testostérone… plusieurs contraceptions masculines existent, mais elles sont méconnues et peu répandues.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\7EZLQMWC\\contraception-masculine-il-n-y-a-aucune-raison-pour-que-cette-charge-repose-uniquement-sur-ma-c.html}
}

@online{ContraceptionMasculineComment2023,
  title = {Contraception masculine : comment fabriquer son slip contraceptif ? Un atelier organisé à Concarneau},
  shorttitle = {Contraception masculine},
  date = {2023-03-13T18:58:31Z},
  url = {https://www.ouest-france.fr/bretagne/concarneau-29900/contraception-masculine-comment-fabriquer-son-slip-contraceptif-un-atelier-organise-a-concarneau-280151f2-c173-11ed-b405-e8b9e5319b6d},
  urldate = {2023-05-18},
  abstract = {Le collectif Thomas Bouloù organise, à la librairie Au Bal, à Concarneau (Finistère), ce mardi 14 mars 2023, un atelier de couture pour réaliser soi-même son slip contraceptif.},
  langid = {french},
  organization = {{Ouest-France.fr}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\H29KJLY9\\contraception-masculine-comment-fabriquer-son-slip-contraceptif-un-atelier-organise-a-concarnea.html}
}

@video{ContraceptionMasculinePilule,
  entrysubtype = {video},
  title = {La contraception masculine : la pilule contraceptive pour les hommes | INA},
  shorttitle = {La contraception masculine},
  url = {https://www.ina.fr/ina-eclaire-actu/video/3083092001015/la-contraception-masculine-la-pilule-contraceptive-pour-les-hommes},
  urldate = {2023-06-05},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\E4Z7STX4\\la-contraception-masculine-la-pilule-contraceptive-pour-les-hommes.html}
}

@online{ContraceptionMasculineScience,
  title = {Contraception masculine: la science progresse dans tous les sens},
  shorttitle = {Contraception masculine},
  url = {https://www.liberation.fr/societe/sante/contraception-masculine-la-science-progresse-dans-tous-les-sens-20220823_HCNSVS5RJJD4JFJ7UDGHMFTYSU/},
  urldate = {2023-05-19},
  abstract = {Des méthodes contraceptives sont testées depuis des années mais sont loin d’être toutes opérationnelles. Le spectre des~solutions est toutefois large, du préservatif au sous-vêtement élastique.},
  langid = {french},
  organization = {{Libération}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\DGKPX9YN\\contraception-masculine-la-science-progresse-dans-tous-les-sens-20220823_HCNSVS5RJJD4JFJ7UDGHMF.html}
}

@online{ContraceptionReunionINA,
  title = {Contraception : Réunion | INA},
  shorttitle = {Contraception},
  url = {https://www.ina.fr/ina-eclaire-actu/publicite/pub1396556093/contraception-reunion},
  urldate = {2023-06-05},
  langid = {french},
  organization = {{ina.fr}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\NHRRLIDF\\contraception-reunion.html}
}

@article{ContraceptionSeDecline1982,
  entrysubtype = {newspaper},
  title = {La contraception se décline au masculin},
  date = {1982-02-27},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/archives/article/1982/02/27/la-contraception-se-decline-au-masculin_2885260_1819218.html},
  urldate = {2023-03-06},
  abstract = {Un groupe de dix hommes a commencé, en mars 1981, à Lyon, une expérience contraceptive hormonale. Peu avant la fin de leur},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\IV3YEYMP\\la-contraception-se-decline-au-masculin_2885260_1819218.html}
}

@online{ContraceptionsMasculinesCa,
  title = {Les contraceptions "masculines" ça existe ? Et oui !!},
  shorttitle = {Les contraceptions "masculines" ça existe ?},
  url = {https://www.planning-familial.org/fr/le-planning-familial-de-gironde-33/contraception/les-contraceptions-masculines-ca-existe-et-oui},
  urldate = {2023-03-02},
  langid = {french},
  organization = {{Le planning familial}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KQMX7C2F\\les-contraceptions-masculines-ca-existe-et-oui.html}
}

@inreference{Cryptorchidie2023,
  title = {Cryptorchidie},
  booktitle = {Wikipédia},
  date = {2023-01-31T14:49:53Z},
  url = {https://fr.wikipedia.org/w/index.php?title=Cryptorchidie&oldid=200954426},
  urldate = {2023-03-07},
  abstract = {La cryptorchidie, appelée aussi trouble de la migration du testicule, ou plus communément testicule mal descendu, est l'absence d'un ou des deux testicules dans le scrotum (position normale introscrotale chez l'homme et chez les animaux à testicules externes). Elle inclut l’ectopie testiculaire, qui est l'insertion du testicule dans un autre endroit, hors des bourses et de son trajet normal, en raison d'un arrêt de la migration du testicule lors de son trajet de descente ; entre la région lombaire où il se forme et son emplacement naturel dans le scrotum.  Le testicule est dit ectopique s'il se trouve au niveau crural ou plus haut si sa descente a été bloquée. Ces deux anomalies, notamment si associées à un hypospadias ou micropénis peuvent être un des éléments du syndrome de dysgénésie testiculaire. Dans certains cas, il peut y avoir doute sur le sexe de l'individu (« ambiguïté sexuelle » ou intersexe)},
  langid = {french},
  annotation = {Page Version ID: 200954426},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\Z2E2KGA3\\Cryptorchidie.html}
}

@inreference{Cryptorchidie2023a,
  title = {Cryptorchidie},
  booktitle = {Wikipédia},
  date = {2023-04-28T13:14:34Z},
  url = {https://fr.wikipedia.org/w/index.php?title=Cryptorchidie&oldid=203755606},
  urldate = {2023-05-18},
  abstract = {La cryptorchidie, appelée aussi trouble de la migration du testicule, ou plus communément testicule mal descendu, est l'absence d'un ou des deux testicules dans le scrotum (position normale introscrotale chez l'homme et chez les animaux à testicules externes). Elle inclut l’ectopie testiculaire, qui est l'insertion du testicule dans un autre endroit, hors des bourses et de son trajet normal, en raison d'un arrêt de la migration du testicule lors de son trajet de descente ; entre la région lombaire où il se forme et son emplacement naturel dans le scrotum.  Le testicule est dit ectopique s'il se trouve au niveau crural ou plus haut si sa descente a été bloquée. Ces deux anomalies, notamment si associées à un hypospadias ou micropénis peuvent être un des éléments du syndrome de dysgénésie testiculaire. Dans certains cas, il peut y avoir doute sur le sexe de l'individu (« ambiguïté sexuelle » ou intersexe)},
  langid = {french},
  annotation = {Page Version ID: 203755606},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\NKZ56EIB\\Cryptorchidie.html}
}

@online{CryptorchidieOuTesticule,
  title = {Cryptorchidie ou testicule non descendu : diagnostic et évolution},
  shorttitle = {Cryptorchidie ou testicule non descendu},
  url = {https://www.ameli.fr/assure/sante/themes/cryptorchidie-testicule-non-descendu-ectopie-testiculaire/diagnostic-evolution},
  urldate = {2023-05-18},
  abstract = {Le diagnostic du testicule non descendu repose sur la palpation des bourses du petit garçon à la naissance et au cours de ses premiers mois de vie.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\PQXQVHDP\\diagnostic-evolution.html}
}

@inreference{Cryptorchidism2023,
  title = {Cryptorchidism},
  booktitle = {Wikipedia},
  date = {2023-02-07T22:35:29Z},
  url = {https://en.wikipedia.org/w/index.php?title=Cryptorchidism&oldid=1138076354},
  urldate = {2023-05-18},
  abstract = {Cryptorchidism, also known as undescended testis, is the failure of one or both testes to descend into the scrotum. The word is from Greek κρυπτός (kryptos) 'hidden' and ὄρχις (orchis) 'testicle'. It is the most common birth defect of the male genital tract. About 3\% of full-term and 30\% of premature infant boys are born with at least one undescended testis. However, about 80\% of cryptorchid testes descend by the first year of life (the majority within three months), making the true incidence of cryptorchidism around 1\% overall. Cryptorchidism may develop after infancy, sometimes as late as young adulthood, but that is exceptional. Cryptorchidism is distinct from monorchism, the condition of having only one testicle. Though the condition may occur on one or both sides, it more commonly affects the right testis.A testis absent from the normal scrotal position may be: Anywhere along the "path of descent" from high in the posterior (retroperitoneal) abdomen, just below the kidney, to the inguinal ring In the inguinal canal Ectopic, having "wandered" from the path of descent, usually outside the inguinal canal and sometimes even under the skin of the thigh, the perineum, the opposite scrotum, or the femoral canal Undeveloped (hypoplastic) or severely abnormal (dysgenetic) Missing (also see anorchia).About two-thirds of cases without other abnormalities are unilateral; most of the other third involve both testes. In 90\% of cases, an undescended testis can be felt in the inguinal canal. In a small minority of cases, missing testes may be found in the abdomen or appear to be nonexistent (truly "hidden"). Undescended testes are associated with reduced fertility, increased risk of testicular germ-cell tumors, and psychological problems when fully-grown. Undescended testes are also more susceptible to testicular torsion (and subsequent infarction) and inguinal hernias. Without intervention, an undescended testicle will usually descend during the first year of life, but to reduce these risks, undescended testes can be brought into the scrotum in infancy by a surgical procedure called an orchiopexy.Although cryptorchidism nearly always refers to congenital absence or maldescent, a testis observed in the scrotum in early infancy can occasionally "reascend" (move back up) into the inguinal canal. A testis that can readily move or be moved between the scrotum and canal is referred to as retractile. Cryptorchidism, hypospadias, testicular cancer, and poor semen quality make up the syndrome known as testicular dysgenesis syndrome.},
  langid = {english},
  annotation = {Page Version ID: 1138076354},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\44P22FZB\\Cryptorchidism.html}
}

@video{DebatPreservatifsDans,
  entrysubtype = {video},
  title = {Débat sur les préservatifs dans les lycées | INA},
  url = {https://www.ina.fr/ina-eclaire-actu/video/3549234001021/debat-sur-les-preservatifs-dans-les-lycees},
  urldate = {2023-06-05},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\9G9AJJN4\\debat-sur-les-preservatifs-dans-les-lycees.html}
}

@article{decraenPlacebosPlaceboEffects1999,
  title = {Placebos and Placebo Effects in Medicine: Historical Overview},
  shorttitle = {Placebos and Placebo Effects in Medicine},
  author = {De Craen, Anton J M and Kaptchuk, Ted J and Tijssen, Jan G P and Kleijnen, J},
  date = {1999-10},
  journaltitle = {Journal of the Royal Society of Medicine},
  shortjournal = {J R Soc Med},
  volume = {92},
  number = {10},
  pages = {511--515},
  issn = {0141-0768, 1758-1095},
  doi = {10.1177/014107689909201005},
  url = {http://journals.sagepub.com/doi/10.1177/014107689909201005},
  urldate = {2023-03-10},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\DEHICDUM\\De Craen et al. - 1999 - Placebos and placebo effects in medicine historic.pdf}
}

@video{denisvanwaerebekeJamesOuRoman2018,
  entrysubtype = {video},
  title = {James Ou Le Roman d'un Médicament},
  editora = {{Denis van Waerebeke} and {Jimmy Audoin} and {Ruelgo} and {Vicent Bordelais} and {Claire lise} and {Carine Leblanc} and {Martine Zwerin}},
  editoratype = {scriptwriter},
  date = {2018-11-15},
  url = {https://www.youtube.com/watch?v=DtuHTgCN68Y},
  urldate = {2023-03-10},
  abstract = {Cette molécule-là ira loin ! Sélectionnée parmi des milliers de molécules, James (c'est son nom) est passée à la moulinette des essais chimiques, puis thérapeutiques... Un protocole hyper rigoureux raconté avec clarté et humour.}
}

@online{DeveloppementMedicamentInserm,
  title = {Développement du médicament - Inserm, La science pour la santé},
  url = {https://www.inserm.fr/dossier/medicament-developpement/},
  urldate = {2023-03-10},
  abstract = {Phase préclinique, clinique, obtention de l’autorisation de mise sur le marché… Près de 15 ans sont nécessaires pour qu’une molécule d’intérêt thérapeutique devienne un « vrai médicament » (hors dispositifs médicaux). Un parcours long et très réglementé qui aura raison de nombreuses molécules candidates se révélant finalement mal tolérées ou…},
  langid = {french},
  organization = {{Inserm}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\JX7NXESD\\medicament-developpement.html}
}

@online{DocumentSansTitre,
  title = {Document sans titre},
  url = {https://docs.google.com/document/u/0/d/1PS4dyNbeTdl8silYYTTwjHrqAgZ6Kz1Oxr2Uqg8qU-Y/edit?usp=embed_facebook},
  urldate = {2023-03-15},
  langid = {french},
  organization = {{Google Docs}}
}

@article{dormanModelingImpactNovel2018,
  title = {Modeling the Impact of Novel Male Contraceptive Methods on Reductions in Unintended Pregnancies in {{Nigeria}}, {{South Africa}}, and the {{United States}}},
  author = {Dorman, Emily and Perry, Brian and Polis, Chelsea B. and Campo-Engelstein, Lisa and Shattuck, Dominick and Hamlin, Aaron and Aiken, Abigail and Trussell, James and Sokal, David},
  date = {2018-01},
  journaltitle = {Contraception},
  shortjournal = {Contraception},
  volume = {97},
  number = {1},
  pages = {62--69},
  issn = {00107824},
  doi = {10.1016/j.contraception.2017.08.015},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S0010782417304304},
  urldate = {2023-05-22},
  abstract = {Objective: We modeled the potential impact of novel male contraceptive methods on averting unintended pregnancies in the United States, South Africa, and Nigeria. Study design: We used an established methodology for calculating the number of couple-years of protection provided by a given contraceptive method mix. We compared a “current scenario” (reflecting current use of existing methods in each country) against “future scenarios,” (reflecting whether a male oral pill or a reversible vas occlusion was introduced) in order to estimate the impact on unintended pregnancies averted. Where possible, we based our assumptions on acceptability data from studies on uptake of novel male contraceptive methods. Results: Assuming that only 10\% of interested men would take up a novel male method and that users would comprise both switchers (from existing methods) and brand-new users of contraception, the model estimated that introducing the male pill or reversible vas occlusion would decrease unintended pregnancies by 3.5\% to 5.2\% in the United States, by 3.2\% to 5\% in South Africa, and by 30.4\% to 38\% in Nigeria. Alternative model scenarios are presented assuming uptake as high as 15\% and as low as 5\% in each location. Model results were sensitive to assumptions regarding novel method uptake and proportion of switchers vs. new users. Conclusion: Even under conservative assumptions, the introduction of a male pill or temporary vas occlusion could meaningfully contribute to averting unintended pregnancies in a variety of contexts, especially in settings where current use of contraception is low. Implications: Novel male contraceptives could play a meaningful role in averting unintended pregnancies in a variety of contexts. The potential impact is especially great in settings where current use of contraception is low and if novel methods can attract new contraceptive users. © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\DFBQQGEC\\Dorman et al. - 2018 - Modeling the impact of novel male contraceptive me.pdf}
}

@online{EfficaciteMoyensContraceptifs,
  title = {Efficacité des moyens contraceptifs},
  url = {https://www.ameli.fr/assure/sante/themes/contraception/efficacite-moyens-contraceptifs},
  urldate = {2023-05-01},
  abstract = {Aucun moyen contraceptif n’est efficace à 100 \%. On distingue l’efficacité théorique (indice de Pearl) et l’efficacité pratique.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\LLDNEMVD\\efficacite-moyens-contraceptifs.html}
}

@video{EssaisPreservatifsINA,
  entrysubtype = {video},
  title = {Essais préservatifs | INA},
  url = {https://www.ina.fr/ina-eclaire-actu/video/cab87005020/essais-preservatifs},
  urldate = {2023-06-05},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\53NLRNEG\\essais-preservatifs.html}
}

@misc{flegmusPreservatifMasculinEnroule2023,
  title = {Préservatif masculin enroulé},
  author = {{Flegmus}},
  date = {2023-04-20T19:08:19Z},
  url = {https://fr.wikipedia.org/w/index.php?title=Pr%C3%A9servatif&oldid=203527478},
  urldate = {2023-05-01},
  abstract = {Le préservatif ou condom (ou capote, plus familier, en Suisse, au Québec et en France) est un étui mince et souple, imperméable au sang, au sperme ainsi qu'aux sécrétions vaginales et péniennes, fabriqué en latex ou en polyuréthane. Il en existe deux types : le préservatif externe (masculin) et le préservatif interne (féminin). Le premier est aussi nommé plus familièrement « capote » en français européen. Le préservatif s'avère être très efficace pour empêcher la transmission des infections sexuellement transmissibles (IST) par les sécrétions vaginales, péniennes et le sperme mais n'offre pas de protection face aux IST présentes sur les surfaces cutanées de la zone génitale. Ainsi le préservatif, correctement utilisé lors d'une relation sexuelle avec pénétration, est le seul contraceptif qui protège de la transmission du VIH et de l'hépatite B. Il ne constitue en revanche pas une protection efficace contre d'autres IST occasionnant un nombre important de décès, comme la syphilis (30\% de protection seulement) ou encore le papillomavirus humain , responsable de plusieurs types de cancers dont le cancer du col de l'utérus et contre lequel seule la vaccination s'avère efficace. Enfin, il ne permet pas non plus de se protéger contre l'herpès génital responsable de conséquences psychologiques et sociales importantes pour la personne atteinte et dont la transmission au fœtus durant l'accouchement, appelée herpès néonatal, occasionne une importante mortalité et des séquelles lourdes.},
  langid = {french},
  annotation = {Page Version ID: 203527478},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\U2Z6AFKT\\Préservatif.html}
}

@video{FrancaisPreservatifRetour,
  entrysubtype = {video},
  title = {Les Français et le préservatif, retour à la mentalité des années 80 | INA},
  url = {https://www.ina.fr/ina-eclaire-actu/video/s715246_001/les-francais-et-le-preservatif-retour-a-la-mentalite-des-annees-80},
  urldate = {2023-06-05},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\4LTLRAM8\\les-francais-et-le-preservatif-retour-a-la-mentalite-des-annees-80.html}
}

@article{freeMaleContraceptionPrescription,
  title = {Male {{Contraception Without Prescription}}},
  author = {Free, Michael J and Alexander, Nancy J},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\35CST9NT\\Free et Alexander - Male Contraception Without Prescription.pdf}
}

@article{glasierWouldWomenTrust,
  title = {Would Women Trust Their Partners to Use a Male Pill?},
  author = {Glasier, A F and Anakwe, R and Everington, D and Martin, C W and Ho, P C and Anderson, R A},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\UEXZYXTY\\Glasier et al. - Would women trust their partners to use a male pil.pdf}
}

@article{GratuiteContraceptionPour2021,
  entrysubtype = {newspaper},
  title = {La gratuité de la contraception pour les femmes de 18 à 25 ans, une mesure adoptée à l’Assemblée nationale},
  date = {2021-10-23},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/sante/article/2021/10/23/contraception-l-assemblee-nationale-adopte-a-l-unanimite-la-gratuite-pour-les-femmes-de-18-a-25-ans_6099612_1651302.html},
  urldate = {2023-04-05},
  abstract = {Trois millions de jeunes femmes sont potentiellement concernées par ce dispositif qui entrera en vigueur le 1er~janvier~2022.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\REZUBD22\\contraception-l-assemblee-nationale-adopte-a-l-unanimite-la-gratuite-pour-les-femmes-de-18-a-25.html}
}

@article{guerinContraceptionMasculineHormonale1996,
  title = {Contraception masculine hormonale},
  author = {Guerin, J. F.},
  date = {1996-09},
  journaltitle = {Andrologie},
  shortjournal = {Androl.},
  volume = {6},
  number = {3},
  pages = {259--265},
  issn = {1166-2654, 1760-5377},
  doi = {10.1007/BF03035279},
  url = {http://link.springer.com/10.1007/BF03035279},
  urldate = {2023-05-08},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\NNBEY3DJ\\Guerin - 1996 - Contraception masculine hormonale.pdf}
}

@book{guillaumedaudinContraceptesEnqueteDernier2022,
  title = {Les contraceptés enquête sur le dernier tabou},
  author = {{Guillaume Daudin} and {Stéphane Jourdain} and {Caroline Lee}},
  date = {2022-03},
  publisher = {{Steinkis}},
  isbn = {978-2-36846-430-4},
  langid = {french},
  pagetotal = {143}
}

@inreference{HeatbasedContraception2023,
  title = {Heat-Based Contraception},
  booktitle = {Wikipedia},
  date = {2023-05-09T23:50:04Z},
  url = {https://en.wikipedia.org/w/index.php?title=Heat-based_contraception&oldid=1154055159},
  urldate = {2023-05-17},
  abstract = {An alternative male contraceptive method involves heating the testicles so that they cannot produce sperm.  Sperm are best produced at a temperature slightly below body temperature. The muscles around a male's scrotum involuntarily tighten if the man's body temperature drops, and they loosen, allowing the testes to hang, if the body temperature rises. This is the body's way of keeping the sperm at an ideal temperature. This means that sperm production can be disrupted with increased temperature.  Some suggest exposure to high temperatures (116 °F equal to 47 °C) can affect fertility for months.Male thermal contraceptive methods (MTC) derive their effectiveness from the alteration of the thermoregulatory function of the scrotum. When this function is altered – by wearing tight underwear, being exposed to a high outside temperature, or by developing a fever, fertility may be impaired. Methods used include hot water applied to the scrotum, heat generated by ultrasound, and artificial cryptorchidism (holding the testicles inside the abdomen) using specialized briefs.  One of the initial experiments resulted in partial infertility lasting more than four years. Initial experiments suggest it is effective and safe, though there have not been long-term studies to determine if it has any side effects on the body after reversal.},
  langid = {english},
  annotation = {Page Version ID: 1154055159},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\RFK8HH4E\\Heat-based_contraception.html}
}

@article{heinemannAttitudesMaleFertility2005,
  title = {Attitudes toward Male Fertility Control: Results of a Multinational Survey on Four Continents},
  shorttitle = {Attitudes toward Male Fertility Control},
  author = {Heinemann, Klaas and Saad, Farid and Wiesemes, Martin and White, Steven and Heinemann, Lothar},
  date = {2005-02-01},
  journaltitle = {Human Reproduction},
  volume = {20},
  number = {2},
  pages = {549--556},
  issn = {1460-2350, 0268-1161},
  doi = {10.1093/humrep/deh574},
  url = {http://academic.oup.com/humrep/article/20/2/549/603220/Attitudes-toward-male-fertility-control-results-of},
  urldate = {2023-02-22},
  abstract = {BACKGROUND: Following extensive research activity to develop an effective agent to control male fertility, such a product may be available for use within ,5 years. However, little is known concerning contraceptive knowledge, desires and attitudes of men in different countries, and their acceptance of male fertility control (MFC). METHODS: A survey of {$>$} 9000 males aged 18 – 50 years was performed in nine countries on four continents in 2002. The objective was to compare, on a cross-cultural basis, the knowledge, attitudes and acceptability of MFC among men and assess their willingness to use such a method. RESULTS: Between 50 and 83\% of the male respondents currently use contraceptive methods, and 55 – 81.5\% reported that both partners participate in selecting the method of contraception employed. Overall acceptance of hormonal MFC was high ({$>$}55\%), with 28.5– 71.4\% of survey participants of various nationalities expressing the willingness to use such a method. CONCLUSION: While MFC appears to be well accepted overall, the willingness to use this type of contraception varies widely between differing population groups. The specific characteristics and profile of any MFC product will have to be carefully evaluated to accurately assess its acceptance, both by men and their female partners.},
  langid = {english},
  keywords = {article,avis,masculin},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\F23P9W8X\\Heinemann et al. - 2005 - Attitudes toward male fertility control results o.pdf}
}

@online{HistoriqueArdecom,
  title = {Historique d’Ardecom |},
  url = {https://www.contraceptionmasculine.fr/historique-dardecom/},
  urldate = {2023-05-20},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\FGAIHF3L\\historique-dardecom.html}
}

@online{HommesMisEnceintes2010,
  title = {Des hommes mis enceintes pour les sensibiliser à la contraception},
  date = {2010-04-09T00:00:00+02:00},
  url = {https://www.20minutes.fr/france/396824-20100409-hommes-mis-enceintes-sensibiliser-a-contraception},
  urldate = {2023-06-05},
  abstract = {C'est le principe de la campagne du ministère de la Santé sur les grossesses non-désirées...},
  langid = {french},
  organization = {{www.20minutes.fr}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\VKLM5KFQ\\396824-20100409-hommes-mis-enceintes-sensibiliser-a-contraception.html}
}

@online{huetMeetPioneersTurning2023,
  title = {Meet the Pioneers Turning Birth Control into a Male Affair},
  author = {Huet, Natalie},
  date = {2023-04-03},
  url = {https://www.euronews.com/next/2023/04/03/future-birth-control-couples-testing-experimental-male-contraceptives-nestorone-gel},
  urldate = {2023-04-05},
  abstract = {From homemade jockstraps to a shoulder gel that slashes sperm counts, these couples are testing new male contraceptives to better share the burden of birth control.},
  langid = {english},
  organization = {{euronews}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\9G3MENF8\\future-birth-control-couples-testing-experimental-male-contraceptives-nestorone-gel.html}
}

@inreference{HypothalamicPituitaryGonadal2022,
  title = {Hypothalamic–Pituitary–Gonadal Axis},
  booktitle = {Wikipedia},
  date = {2022-09-08T08:18:14Z},
  url = {https://en.wikipedia.org/w/index.php?title=Hypothalamic%E2%80%93pituitary%E2%80%93gonadal_axis&oldid=1109152185},
  urldate = {2023-05-08},
  abstract = {The hypothalamic–pituitary–gonadal axis (HPG axis, also known as the hypothalamic–pituitary–ovarian/testicular axis) refers to the hypothalamus, pituitary gland, and gonadal glands as if these individual endocrine glands were a single entity. Because these glands often act in concert, physiologists and endocrinologists find it convenient and descriptive to speak of them as a single system. The HPG axis plays a critical part in the development and regulation of a number of the body's systems, such as the reproductive and immune systems. Fluctuations in this axis cause changes in the hormones produced by each gland and have various local and systemic effects on the body. The axis controls development, reproduction, and aging in animals. Gonadotropin-releasing hormone (GnRH) is secreted from the hypothalamus by GnRH-expressing neurons. The anterior portion of the pituitary gland produces luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and the gonads produce estrogen and testosterone. In oviparous organisms (e.g. fish, reptiles, amphibians, birds), the HPG axis is commonly referred to as the hypothalamus-pituitary-gonadal-liver axis (HPGL-axis) in females. Many egg-yolk and chorionic proteins are synthesized heterologously in the liver, which are necessary for ovocyte growth and development. Examples of such necessary liver proteins are vitellogenin and choriogenin. The HPA, HPG, and HPT axes are three pathways in which the hypothalamus and pituitary direct neuroendocrine function.},
  langid = {english},
  annotation = {Page Version ID: 1109152185},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\DEBUWZ28\\Hypothalamic–pituitary–gonadal_axis.html}
}

@online{ImmunocontraceptionWikipedia,
  title = {Immunocontraception - {{Wikipedia}}},
  url = {https://en.wikipedia.org/wiki/Immunocontraception?oldformat=true},
  urldate = {2023-05-18}
}

@video{inaactuPilulePourHomme2019,
  entrysubtype = {video},
  title = {Pilule Pour Homme, 50 Ans Qu’elle Passe Mal | {{Franceinfo INA}}},
  editor = {{INA Actu}},
  editortype = {director},
  date = {2019-09-26},
  url = {https://www.youtube.com/watch?v=4-EBXMrEKIE},
  urldate = {2023-06-04},
  abstract = {Abonnez-vous  http://bit.ly/inaactu Retour vers l'info | Ludivine Lopez | 26/09/2019 C’est la journée mondiale de la contraception aujourd’hui. Une journée soutenue par de nombreuses organisations non-gouvernementales dans plusieurs pays. Son objectif : sensibiliser les plus jeunes aux différents moyens de contraception et réduire le nombre de grossesses non désirées dans le monde. Pour l’occasion l’INA s’est intéressé à la pilule pour homme. Ce contraceptif était déjà à l’étude dans les années 70… et 50 ans plus tard les choses n’ont pas vraiment changé.  Images d'archive INA Institut National de l'Audiovisuel http://www.ina.fr \#INA \#Actu}
}

@video{inapolitiqueCampagneContraception2012,
  entrysubtype = {video},
  title = {Campagne Contraception},
  editor = {{INA Politique}},
  editortype = {director},
  date = {2012-07-09},
  url = {https://www.youtube.com/watch?v=vEoihZ2x_m8},
  urldate = {2023-06-05},
  abstract = {27 octobre 1992 Lancement aujourd'hui d'une nouvelle campagne d'information sur la contraception s'adressant principalement aux adolescents. Le problème était de parler de la sexualité sans choquer les parents. Une première version du spot télévisé a dû être abandonnée, et c'est le Premier ministre en personne qui aurait demandé une version moins directe. - Extrait du spot télévisé mettant en scène des adolescents - Interview de Véronique NEIERTZ, secrétaire d'Etat aux Droits de la femme : "Nous avons mis un certain temps à élaborer ce message parce que chacun a sa sensibilité et que les adultes ont beaucoup plus de mal à parler de la sexualité des jeunes, à admettre certaines réalités qui nous sont apparues dans le sondage de l'IFOP que j'ai fait réaliser au mois de décembre et qui montre que les relations sexuelles sont beaucoup plus précoces que pour notre génération"- Images de la conférence de presse de V. NEIERTZ. Affiche "la contraception ça devient simple quand on en parle" comprenant  le numéro d'une permanence téléphonique nationale- bref extrait du spot télévisé : message "la contraception ça devient simple quand on en parle" en incrustation. politique; archive television; archive tv; ina; inna; Institut National de l'Audiovisuel; french tv Images d'archive INA Institut National de l'Audiovisuel http://www.ina.fr Abonnez-vous http://www.youtube.com/subscription\_c... Abonnez-vous http://www.youtube.com/subscription\_c... \#INA \#Politique}
}

@article{khilwaniRISUGMaleContraceptive2020,
  title = {{{RISUG}}® as a Male Contraceptive: Journey from Bench to Bedside},
  shorttitle = {{{RISUG}}® as a Male Contraceptive},
  author = {Khilwani, Barkha and Badar, Ayesha and Ansari, Abdul S. and Lohiya, Nirmal K.},
  date = {2020-02-13},
  journaltitle = {Basic and Clinical Andrology},
  shortjournal = {Basic Clin Androl},
  volume = {30},
  eprint = {32082579},
  eprinttype = {pmid},
  pages = {2},
  issn = {2051-4190},
  doi = {10.1186/s12610-020-0099-1},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017607/},
  urldate = {2023-05-19},
  abstract = {Even after decades of research men still lack reliable and reversible contraceptive methods comparable to female methods of contraception. Traditional methods of male contraception present a high failure rate and also involve high risk both when used for contraception and for protection against sexually transmitted diseases. Various chemical, hormonal, immunological, vas based and herbal methods of contraception have been examined by scientists world over during the past four decades. Among the possible lead approaches, exogenous hormonal contraception, either alone or in combination with progesterone or antiandrogen, is being viewed at low profile because of their insufficiency in inducing uniform suppression of spermatogenesis and steroid related long term complications. As an alternative to vasectomy, among various intravasal devices being examined, RISUG® (Reversible Inhibition of Sperm Under Guidance), a co-polymer of styrene and maleic anhydride offers long term contraception with safety, efficacy and it can be delivered by no-scalpel injection. Thus it is the only male contraceptive procedure currently under Phase- III Clinical Trial. The non-invasive reversal technique, successfully demonstrated in langur monkeys and functional reversal achieved with dimethyl sulphoxide (DMSO) and sodium bicarbonate (NaHCO3) in rats and rabbits with safety at F1 generation (first filial generation) have projected RISUG® as a better alternative to vasectomy. In this narrative review we revisit the long journey of RISUG® beginning with formulation on a bench towards reaching the market as a safe and effective contraceptive method, discussing various milestones and roadblocks of this expedition awaiting the mandatory regulatory clearance from the Government of India. Successful completion of ongoing phase III clinical trials with demonstration of reversal in human volunteers will give an indigenously developed male contraceptive to the world.},
  pmcid = {PMC7017607},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\5JJH3RN9\\Khilwani et al. - 2020 - RISUG® as a male contraceptive journey from bench.pdf}
}

@online{lachaudEgaliteFautPromouvoir2021,
  title = {Égalité : il faut promouvoir la contraception masculine},
  shorttitle = {Égalité},
  author = {Lachaud, Bastien},
  date = {2021-09-21T18:06:11+00:00},
  url = {https://bastienlachaud.fr/2021/09/21/egalite-promouvoir-contraception-masculine/},
  urldate = {2023-04-05},
  abstract = {La contraception est une affaire de partenaires, sa responsabilité n'incombe pas aux femmes. Il faut promouvoir la contraception masculine.},
  langid = {french},
  organization = {{Bastien Lachaud}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KLARR8TU\\egalite-promouvoir-contraception-masculine.html}
}

@video{leblobContraceptionMasculineOu2021,
  entrysubtype = {video},
  title = {Contraception Masculine : Où En Est-on ? | {{Reportage}}},
  shorttitle = {Contraception Masculine},
  editor = {{Le Blob}},
  editortype = {director},
  date = {2021-11-29},
  url = {https://www.youtube.com/watch?v=8i6Z2BAaDsE},
  urldate = {2023-05-14},
  abstract = {Autorisée depuis plus d'un demi-siècle en France, la contraception est très majoritairement le fait des femmes. Alors, à quand la contraception masculine ? Où en sont les recherches dans ce domaine ? Réalisation : Anaïs Poncet Production : Universcience 2021 Tous nos films sur https://LeBlob.fr}
}

@article{lohiyaRISUGIntravasalInjectable2014,
  title = {{{RISUG}}: {{An}} Intravasal Injectable Male Contraceptive},
  author = {Lohiya, N K and Alam, I and Hussain, M and Khan, S R and Ansari, A S},
  date = {2014},
  journaltitle = {INDIAN J MED RES},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\5GCT53E8\\IJMR-140-63.pdf;C\:\\Users\\esteb\\Zotero\\storage\\9D7ZDDQW\\274948_spf00001571.pdf}
}

@article{longUpdateNovelHormonal2021,
  title = {Update on {{Novel Hormonal}} and {{Nonhormonal Male Contraceptive Development}}},
  author = {Long, Jill E and Lee, Min S and Blithe, Diana L},
  date = {2021-05-13},
  journaltitle = {The Journal of Clinical Endocrinology \& Metabolism},
  volume = {106},
  number = {6},
  pages = {e2381-e2392},
  issn = {0021-972X, 1945-7197},
  doi = {10.1210/clinem/dgab034},
  url = {https://academic.oup.com/jcem/article/106/6/e2381/6108319},
  urldate = {2023-02-22},
  abstract = {Background:\hspace{0.6em}The advent of new methods of male contraception would increase contraceptive options for men and women and advance male contraceptive agency. Pharmaceutical R\&D for male contraception has been dormant since the 1990s. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has supported a contraceptive development program since 1969 and supports most ongoing hormonal male contraceptive development. Nonhormonal methods are in earlier stages of development.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\98B4LLZG\\Long et al. - 2021 - Update on Novel Hormonal and Nonhormonal Male Cont.pdf}
}

@online{MaladiesInfectionsSexuellement,
  title = {Maladies et infections sexuellement transmissibles},
  url = {https://www.ameli.fr/assure/sante/themes/mst-ist/maladies-infections-sexuellement-transmissibles},
  urldate = {2023-05-01},
  abstract = {Les infections sexuellement transmissibles ou IST sont des infections dues à des bactéries, virus et parasites, et transmises par voie sexuelle.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\TCG7WJMJ\\maladies-infections-sexuellement-transmissibles.html}
}

@article{manettiUpdateMaleHormonal2010,
  title = {Update on {{Male Hormonal Contraception}}: {{Is}} the {{Vasectomy}} in {{Jeopardy}}?},
  shorttitle = {Update on {{Male Hormonal Contraception}}},
  author = {Manetti, G J and Honig, S C},
  date = {2010-05},
  journaltitle = {International Journal of Impotence Research},
  shortjournal = {Int J Impot Res},
  volume = {22},
  number = {3},
  pages = {159--170},
  issn = {0955-9930, 1476-5489},
  doi = {10.1038/ijir.2010.2},
  url = {https://www.nature.com/articles/ijir20102},
  urldate = {2023-02-22},
  langid = {english},
  keywords = {masculine}
}

@article{manettiUpdateMaleHormonal2010a,
  title = {Update on {{Male Hormonal Contraception}}: {{Is}} the {{Vasectomy}} in {{Jeopardy}}?},
  shorttitle = {Update on {{Male Hormonal Contraception}}},
  author = {Manetti, G J and Honig, S C},
  date = {2010-05},
  journaltitle = {International Journal of Impotence Research},
  shortjournal = {Int J Impot Res},
  volume = {22},
  number = {3},
  pages = {159--170},
  issn = {0955-9930, 1476-5489},
  doi = {10.1038/ijir.2010.2},
  url = {https://www.nature.com/articles/ijir20102},
  urldate = {2023-02-22},
  langid = {english},
  keywords = {article,masculine}
}

@article{manettiUpdateMaleHormonal2010b,
  title = {Update on {{Male Hormonal Contraception}}: {{Is}} the {{Vasectomy}} in {{Jeopardy}}?},
  shorttitle = {Update on {{Male Hormonal Contraception}}},
  author = {Manetti, G J and Honig, S C},
  date = {2010-05},
  journaltitle = {International Journal of Impotence Research},
  shortjournal = {Int J Impot Res},
  volume = {22},
  number = {3},
  pages = {159--170},
  issn = {0955-9930, 1476-5489},
  doi = {10.1038/ijir.2010.2},
  url = {https://www.nature.com/articles/ijir20102},
  urldate = {2023-02-22},
  langid = {english},
  keywords = {article,masculin},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\K4ZDUSEL\\Manetti et Honig - 2010 - Update on Male Hormonal Contraception Is the Vase.pdf}
}

@article{marlenethomasContraceptionMasculineArretez2022,
  entrysubtype = {newspaper},
  title = {Contraception masculine arrêtez de vous dorer la pilule !},
  author = {{Marlène Thomas} and {Dov Alfon} and {Viriginie Ballet} and {Camille Gévaudant}},
  date = {2022-08-23},
  journaltitle = {Libération},
  pages = {2--5},
  langid = {french}
}

@video{mccannparisINPESContraception2011,
  entrysubtype = {video},
  title = {{{INPES Contraception}}},
  editor = {{McCann Paris}},
  editortype = {director},
  date = {2011-10-27},
  url = {https://www.youtube.com/watch?v=f1YJgzDZTVc},
  urldate = {2023-06-05},
  abstract = {L'INPES et le ministère en charge de la Santé lancent une nouvelle campagne de communication qui s'adresse aux femmes de 20 à 35 ans sous contraceptif oral. Elle interroge l'adéquation de leur contraception avec leur situation personnelle et rappelle qu'en cas d'oublis fréquents, d'autres modes de contraception peuvent être envisagés. Le spot signé McCann Paris rappelle sous forme et décalé  la difficulté de prendre au quotidien un contraceptif, sans culpabiliser les femmes qui en sont les premières victimes. Il propose une solution concrète pour les oublis fréquents : le changement de mode de contraception.}
}

@article{mclaughlinThereRoleImmunocontraception2011,
  title = {Is There a Role for Immunocontraception?},
  author = {McLaughlin, E.A. and Aitken, R.J.},
  date = {2011-03},
  journaltitle = {Molecular and Cellular Endocrinology},
  shortjournal = {Molecular and Cellular Endocrinology},
  volume = {335},
  number = {1},
  pages = {78--88},
  issn = {03037207},
  doi = {10.1016/j.mce.2010.04.004},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S0303720710002091},
  urldate = {2023-05-18},
  abstract = {The world’s population is continuing to grow at an alarming rate and yet no novel methods of contraception have been introduced since 1960s. The paucity of our current contraceptive armoury is indicated by the 46 million abortions that are performed each year, largely in developing countries where population growth is greatest. Thus, whatever new forms of fertility control we develop for the next millennium, the particular needs of developing countries should be borne in mind. Contraceptive vaccines have the potential to provide safe, effective, prolonged, reversible protection against pregnancy in a form that can be easily administered in the Third World. In this review we consider the contraceptive targets that might be pursued, how vaccines might be engineered and the problems generated by inter-individual variations in antibody titre. We conclude that the specifications for a safe, effective, reversible vaccine are more likely to be met in animals than man.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\5PPRQEHM\\McLaughlin et Aitken - 2011 - Is there a role for immunocontraception.pdf}
}

@online{medisitePiluleContraceptivePour,
  title = {Pilule contraceptive pour homme : qu'est-ce que la DMAU},
  shorttitle = {Pilule contraceptive pour homme},
  author = {Médisite, La Rédaction},
  url = {https://www.medisite.fr/contraception-pilule-contraceptive-pour-homme-quest-ce-que-la-dmau.5317139.373055.html},
  urldate = {2023-05-13},
  abstract = {La contraception orale est longtemps restée exclusivement féminine. Une pilule contraceptive pour homme a récemment fait son apparition. Elle...},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\GR5ZALSD\\contraception-pilule-contraceptive-pour-homme-quest-ce-que-la-dmau.5317139.373055.html}
}

@online{MethodeThermique,
  title = {Méthode thermique |},
  url = {https://www.contraceptionmasculine.fr/la-methode-thermique/},
  urldate = {2023-05-18},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\T74WP5CZ\\la-methode-thermique.html}
}

@video{MicrotrottoirHommesPour,
  entrysubtype = {video},
  title = {Micro-trottoir : des hommes pour ou contre la contraception masculine | INA},
  shorttitle = {Micro-trottoir},
  url = {https://www.ina.fr/ina-eclaire-actu/video/i17310044/micro-trottoir-des-hommes-pour-ou-contre-la-contraception-masculine},
  urldate = {2023-06-04},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\UF82UWEH\\micro-trottoir-des-hommes-pour-ou-contre-la-contraception-masculine.html}
}

@article{mieussetHyperthermiaHumanSpermatogenesis1987,
  title = {Hyperthermia and Human Spermatogenesis: Enhancement of the Inhibitory Effect Obtained by ‘Artificial Cryptorchidism’},
  shorttitle = {Hyperthermia and Human Spermatogenesis},
  author = {Mieusset, R. and Bujan, L. and Mansat, Arlette and Pontonnier, F. and Grandjean, Hélène},
  date = {1987-08},
  journaltitle = {International Journal of Andrology},
  shortjournal = {Int J Androl},
  volume = {10},
  number = {4},
  pages = {571--580},
  issn = {0105-6263, 1365-2605},
  doi = {10.1111/j.1365-2605.1987.tb00356.x},
  url = {https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2605.1987.tb00356.x},
  urldate = {2023-03-07},
  abstract = {Decreased sperm count and motility were observed in men after induction of local testicular hyperthermia by raising the testicles into the inguinal canal during the day in adult volunteers. A similar technique in which the testicles were better maintained in the inguinal canal resulted in more marked suppression of spermatogenesis. As assessed by the total motile sperm count, the mean inhibitory effect of hyperthermia was at least 97\% after 2 months using this technique. This effect of ‘artificial cryptorchidism’ may be of practical interest in the manipulation of male fertility.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KY3KV885\\Mieusset et al. - 1987 - Hyperthermia and human spermatogenesis enhancemen.pdf}
}

@article{mieussetInhibitingEffectArtificial1985,
  title = {Inhibiting Effect of Artificial Cryptorchidism on Spermatogenesis},
  author = {Mieusset, Roger and Grandjean, Hélène and Mansat, Arlette and Pontonnier, Francis},
  date = {1985-04},
  journaltitle = {Fertility and Sterility},
  shortjournal = {Fertility and Sterility},
  volume = {43},
  number = {4},
  pages = {589--594},
  issn = {00150282},
  doi = {10.1016/S0015-0282(16)48502-X},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S001502821648502X},
  urldate = {2023-03-07},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\YGCQIIBV\\Mieusset et al. - 1985 - Inhibiting effect of artificial cryptorchidism on .pdf}
}

@article{mieussetPotentialMildTesticular1994,
  title = {The Potential of Mild Testicular Heating as a Safe, Effective and Reversible Contraceptive Method for Men},
  author = {Mieusset, Roger and B'Ujan, Louis},
  date = {1994-08},
  journaltitle = {International Journal of Andrology},
  shortjournal = {Int J Androl},
  volume = {17},
  number = {4},
  pages = {186--191},
  issn = {0105-6263, 1365-2605},
  doi = {10.1111/j.1365-2605.1994.tb01241.x},
  url = {https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2605.1994.tb01241.x},
  urldate = {2023-03-07},
  abstract = {A preliminary assessment of the contraceptive efficacy of a daily mild increase (1-2OC) in testicular temperature during waking hours is reported in nine couples using two techniques of non-surgical fixation of the testes close to the inguinal canal. With technique 1, immobilization was achieved by passing the penis and the empty scrotum through a hole made in close-fitting underwear; there was one pregnancy, h m a man who stopped the heating after 7 weeks, for 42 cycles of exposure in three couples. With technique 2, immobilization was achieved by adding a ring of soft material surrounding the hole in the underwear; there was no pregnancy for 117 cycles of exposure in six couples. Reversibility and safety were assessed. These preliminary results suggest that a daily mild increase in testicular temperature could be a potential contraceptive method for men.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\A2N8LD5U\\Mieusset et B'Ujan - 1994 - The potential of mild testicular heating as a safe.pdf}
}

@article{mieussetPotentialMildTesticular1994a,
  title = {The Potential of Mild Testicular Heating as a Safe, Effective and Reversible Contraceptive Method for Men},
  author = {Mieusset, Roger and B'Ujan, Louis},
  date = {1994-08},
  journaltitle = {International Journal of Andrology},
  shortjournal = {Int J Androl},
  volume = {17},
  number = {4},
  pages = {186--191},
  issn = {0105-6263, 1365-2605},
  doi = {10.1111/j.1365-2605.1994.tb01241.x},
  url = {https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2605.1994.tb01241.x},
  urldate = {2023-03-07},
  abstract = {A preliminary assessment of the contraceptive efficacy of a daily mild increase (1-2OC) in testicular temperature during waking hours is reported in nine couples using two techniques of non-surgical fixation of the testes close to the inguinal canal. With technique 1, immobilization was achieved by passing the penis and the empty scrotum through a hole made in close-fitting underwear; there was one pregnancy, h m a man who stopped the heating after 7 weeks, for 42 cycles of exposure in three couples. With technique 2, immobilization was achieved by adding a ring of soft material surrounding the hole in the underwear; there was no pregnancy for 117 cycles of exposure in six couples. Reversibility and safety were assessed. These preliminary results suggest that a daily mild increase in testicular temperature could be a potential contraceptive method for men.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\T8SNNHQY\\Mieusset et B'Ujan - 1994 - The potential of mild testicular heating as a safe.pdf}
}

@online{MuscleCremasterWikipedia,
  title = {Muscle Crémaster — {{Wikipédia}}},
  url = {https://fr.wikipedia.org/wiki/Muscle_cr%C3%A9master?oldformat=true},
  urldate = {2023-05-17},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\SFPMJEQ3\\Muscle_crémaster.html}
}

@online{NoticePatientANDROGEL,
  title = {Notice Patient - {{ANDROGEL}} 16,2 Mg/g, Gel - {{Base}} de Données Publique Des Médicaments},
  url = {https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=68097237&typedoc=N},
  urldate = {2023-05-14},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KDCJTDXF\\affichageDoc.html}
}

@misc{NoticeUtilisationPdf2022,
  title = {Notice d'utilisation.Pdf},
  date = {2022-08-11},
  url = {https://thoreme.com/wp-content/uploads/2022/10/Notice-dutilisation-ANDRO-SWITCH-10-2022.pdf},
  urldate = {2023-05-18},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\AR7Y73D6\\Notice-dutilisation-ANDRO-SWITCH-10-2022.pdf}
}

@online{OuNousTrouver,
  title = {Où nous trouver ? |},
  shorttitle = {Où nous trouver ?},
  url = {https://www.contraceptionmasculine.fr/vie-de-lassociation/ou-nous-trouver/},
  urldate = {2023-05-22},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\FCGMPK9C\\ou-nous-trouver.html}
}

@video{PilulePourHomme,
  entrysubtype = {video},
  title = {La pilule pour homme | INA},
  url = {https://www.ina.fr/ina-eclaire-actu/video/caa7502153601/la-pilule-pour-homme},
  urldate = {2023-06-04},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\MSIDL64P\\la-pilule-pour-homme.html}
}

@online{PlanReversibleMale,
  title = {Plan {{A}}™ | {{Reversible Male Birth Control}}},
  url = {https://www.planaformen.com},
  urldate = {2023-05-19},
  abstract = {Non-hormonal, long-lasting, and reversible male contraception.},
  langid = {american},
  organization = {{Plan A}}
}

@video{PremierePilulePour,
  entrysubtype = {video},
  title = {La première pilule pour homme | INA},
  url = {https://www.ina.fr/ina-eclaire-actu/video/i00002566/la-premiere-pilule-pour-homme},
  urldate = {2023-06-05},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\LDYTRIQU\\la-premiere-pilule-pour-homme.html}
}

@online{PreservatifWikipedia,
  title = {Préservatif — {{Wikipédia}}},
  url = {https://fr.wikipedia.org/wiki/Pr%C3%A9servatif?oldformat=true},
  urldate = {2023-05-01},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\PJSPBZLK\\Préservatif.html}
}

@online{PreventionIST,
  title = {Prévention des IST},
  url = {https://www.ameli.fr/assure/sante/themes/mst-ist/prevention},
  urldate = {2023-05-01},
  abstract = {La prévention des infections sexuellement transmissibles passe principalement par l’utilisation du préservatif et pour certaines par la vaccination.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\EQVRTG5A\\prevention.html}
}

@video{ProfesseurNetterContraception,
  entrysubtype = {video},
  title = {Le professeur Netter sur la contraception masculine et la vasectomie | INA},
  url = {https://www.ina.fr/ina-eclaire-actu/video/i17307025/le-professeur-netter-sur-la-contraception-masculine-et-la-vasectomie},
  urldate = {2023-06-04},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KW6FFLI7\\le-professeur-netter-sur-la-contraception-masculine-et-la-vasectomie.html}
}

@video{PublicitePreservatifsSida,
  entrysubtype = {video},
  title = {Publicité sur les préservatifs et Sida | INA},
  url = {https://www.ina.fr/ina-eclaire-actu/video/cac00014517/publicite-sur-les-preservatifs-et-sida},
  urldate = {2023-06-05},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\6MC4STDP\\publicite-sur-les-preservatifs-et-sida.html}
}

@online{Question41326Assemblee,
  title = {Question N°41326 - {{Assemblée}} Nationale},
  url = {https://questions.assemblee-nationale.fr/q15/15-41326QE.htm},
  urldate = {2023-04-05}
}

@online{Question41326Assembleea,
  title = {Question N°41326 - {{Assemblée}} Nationale},
  url = {https://questions.assemblee-nationale.fr/q15/15-41326QE.htm},
  urldate = {2023-04-05}
}

@online{QuiSommesNous,
  type = {GARCON},
  title = {Qui sommes nous ? | GARCON},
  shorttitle = {Qui sommes nous ?},
  url = {https://garcon.link/qui-sommes-nous/},
  urldate = {2023-05-22},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\ZG896DJ5\\qui-sommes-nous.html}
}

@misc{RapportSocial20202020,
  title = {Rapport Social 2020},
  date = {2020},
  url = {https://www.utbm.fr/wp-content/uploads/2021/09/RapportSocial2020-web.pdf},
  urldate = {2023-05-25},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\VPTCUTJ7\\RapportSocial2020-web.pdf}
}

@online{ResultatsRechercheINA,
  title = {Résultats de Recherche | {{INA}}},
  url = {https://www.ina.fr/recherche?q=pilule+homme&espace=1&sort=pertinence&order=desc},
  urldate = {2023-06-04},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\J7YWDHLI\\recherche.html}
}

@online{ReversibleInhibitionSperm,
  title = {Reversible Inhibition of Sperm under Guidance - {{Wikipedia}}},
  url = {https://en.wikipedia.org/wiki/Reversible%20inhibition%20of%20sperm%20under%20guidance?oldformat=true},
  urldate = {2023-05-19},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\Y8UWWRPP\\Reversible inhibition of sperm under guidance.html}
}

@article{ringheimEvidenceAcceptabilityInjectable1995,
  title = {Evidence for the {{Acceptability}} of an {{Injectable Hormonal Method}} for {{Men}}},
  author = {Ringheim, Karin},
  date = {1995-05},
  journaltitle = {Family Planning Perspectives},
  shortjournal = {Family Planning Perspectives},
  volume = {27},
  number = {3},
  eprint = {2136111},
  eprinttype = {jstor},
  pages = {123},
  issn = {00147354},
  doi = {10.2307/2136111},
  url = {https://www.jstor.org/stable/2136111?origin=crossref},
  urldate = {2023-05-22},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\FYZB5AKR\\Ringheim - 1995 - Evidence for the Acceptability of an Injectable Ho.pdf}
}

@inreference{Risug2021,
  title = {Risug},
  booktitle = {Wikipédia},
  date = {2021-02-11T07:52:00Z},
  url = {https://fr.wikipedia.org/w/index.php?title=Risug&oldid=179797257},
  urldate = {2023-02-22},
  abstract = {Le  RISUG  (Reversible Inhibition of Sperm Under Guidance), anciennement dénommé SMA,  est le nom de développement d'un contraceptif masculin développé à l'Institut indien de technologie de Kharagpur en Inde par le Dr Sujoy K. Guha. Il est actuellement en phase III des essais cliniques[réf. nécessaire] (visant à établir l'efficacité et la tolérance du contraceptif masculin). Ce dernier a été breveté en Inde, en Chine, au Bangladesh, aux États-Unis et au Canada.},
  langid = {french},
  keywords = {masculin},
  annotation = {Page Version ID: 179797257},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\R5PKC8MU\\Risug.html}
}

@online{RisugWikipedia,
  title = {Risug — {{Wikipédia}}},
  url = {https://fr.wikipedia.org/wiki/Risug?oldformat=true},
  urldate = {2023-05-19},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\9AFIFHJP\\Risug.html}
}

@article{rothAcceptabilityTransdermalGelbased2014,
  title = {Acceptability of a Transdermal Gel-Based Male Hormonal Contraceptive in a Randomized Controlled Trial},
  author = {Roth, Mara Y. and Shih, Grace and Ilani, Niloufar and Wang, Christina and Page, Stephanie T. and Bremner, William J. and Swerdloff, Ronald S. and Sitruk-Ware, Regine and Blithe, Diana L. and Amory, John K.},
  date = {2014-10},
  journaltitle = {Contraception},
  shortjournal = {Contraception},
  volume = {90},
  number = {4},
  pages = {407--412},
  issn = {00107824},
  doi = {10.1016/j.contraception.2014.05.013},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S0010782414002947},
  urldate = {2023-05-22},
  abstract = {Objective: Fifty percent of pregnancies in the United States are unintended despite numerous contraceptive methods available to women. The only male contraceptive methods, vasectomy and condoms, are used by 10\% and 16\% of couples respectively. Prior studies have shown efficacy of male hormonal contraceptives in development, but few have evaluated patient acceptability and potential use if commercially available. The objective of this study is to determine if a transdermal gel-based male hormonal contraceptive regimen, containing testosterone and Nestorone® gels, would be acceptable to study participants as a primary contraceptive method. Study Design: As part of a three-arm, 6-month, double-blind, randomized controlled trial of testosterone and nestorone gels at two academic medical centers, subjects completed a questionnaire to assess the acceptability of the regimen. Of the 99 men randomized, 79 provided data for analysis. Results: Overall, 56\% (44/79) of men were satisfied or extremely satisfied with this gel-based method of contraception, and 51\% (40/79) reported they would recommend this method to others. One-third of subjects (26/79) reported they would use this as their primary method of contraception if it were commercially available today. However, men with concerns about sexually transmitted disease were significantly less satisfied than men without such concerns (p=0.03). Conclusions: A majority of the men who volunteered to participate in this trial of an experimental male hormonal contraceptive were satisfied with this transdermal male hormonal contraceptive. If commercially available, a combination of topical nesterone and testosterone gels could provide a reversible, effective method of contraception that is appealing to men.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\5TEIP6XZ\\Roth et al. - 2014 - Acceptability of a transdermal gel-based male horm.pdf}
}

@misc{santepublicfranceChoisirSaContraception2019,
  title = {Choisir sa contraception},
  author = {{Sante public france}},
  editora = {{Service du droit des femmes et de l’égalité} and {Association française pour la contraception} and {Mouvement français pour le planning familial} and {Centre régional d’information et de prévention du sida Île-de-France}},
  editoratype = {collaborator},
  date = {2019-10},
  url = {https://www.santepubliquefrance.fr/content/download/461303/3575583?version=1},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\A5YBTMQ9\\274948_spf00001571.pdf}
}

@article{SexualiteHommesAbsents2023,
  entrysubtype = {newspaper},
  title = {Sexualité : les hommes absents de la conversation},
  shorttitle = {Sexualité},
  date = {2023-04-02},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/m-perso/article/2023/04/02/sexualite-les-hommes-absents-de-la-conversation_6167920_4497916.html},
  urldate = {2023-04-05},
  abstract = {CHRONIQUE. Rares sont les experts à s’exprimer sur les questions sexuelles ou de genre, constate Maïa Mazaurette, la chroniqueuse de «~La Matinale~», qui déplore cette sous-représentation~: la société dans son ensemble bénéficierait de paroles masculines libres et informées.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\Y9XDVGF2\\sexualite-les-hommes-absents-de-la-conversation_6167920_4497916.html}
}

@article{sharmaSafetyEfficacyIntravasal2019,
  title = {Safety \& Efficacy of an Intravasal, One-Time Injectable \& Non-Hormonal Male Contraceptive ({{RISUG}}): {{A}} Clinical Experience},
  shorttitle = {Safety \& Efficacy of an Intravasal, One-Time Injectable \& Non-Hormonal Male Contraceptive ({{RISUG}})},
  author = {Sharma, Radhey Shyam and Mathur, Ajit Kumar and Singh, Rajeev and Das, Hem Chandra and Singh, Gulshan Jeet and Toor, Devinder Pal Singh and Guha, Sujoy Kumar},
  date = {2019-07},
  journaltitle = {The Indian Journal of Medical Research},
  shortjournal = {Indian J Med Res},
  volume = {150},
  number = {1},
  eprint = {31571633},
  eprinttype = {pmid},
  pages = {81--86},
  issn = {0971-5916},
  doi = {10.4103/ijmr.IJMR_635_18},
  abstract = {BACKGROUND \& OBJECTIVES: For improved male contraception, a new polymeric drug molecule - Reversible Inhibition of Sperm under Guidance (RISUG) has been synthesized and has been found to be effective, safe and reversible in various animal species. Phase-I and phase-II clinical trials have confirmed its safety and contraceptive efficacy. The present study was undertaken as a multicentric-limited phase-III clinical trial to test the efficacy and safety of RISUG in human volunteers. METHODS: One hundred and thirty nine young males each having at least two children and living with wife were given 120 μl of RISUG as bilateral vas intraluminal injection. After the single-dose administration, the individuals were followed in respect of general health and semen parameters. Their wives were also followed particularly to determine onset of pregnancy. RESULTS: During the six month follow up, the health of male volunteers and their wives was normal with no significant adverse effects. Temporary scrotal enlargement and mild scrotal and inguinal region pain were manifested in most individuals and resolved within one month without any routine activity impairment. In six individuals, there was injection procedure failure and azoospermia was not achieved. The other 133 individuals had either severe oligozoospermia or azoospermia at the first semen examination one month following RISUG injection; 82.7 per cent individuals had continued azoospermia in the month following first semen examination onwards and the rest 17.3 per cent manifested azoospermia within three to six months. INTERPRETATION \& CONCLUSIONS: RISUG intravasal injection appears to be a safe clinical procedure with no significant adverse effects and has high sustained contraceptive efficacy. The localized intervention and continued contraceptive action on single-dose administration were significant features of the RISUG technology.},
  langid = {english},
  pmcid = {PMC6798614},
  keywords = {Adult,Animals,Azoospermia,Contraception,{Contraceptive Agents, Male},efficacy,Female,Humans,Injections,intravasal male contraceptive,Male,Polyesters,Polystyrenes,Pregnancy,RISUG,safety,Semen,Semen Analysis,sperm,Spermatozoa,Spouses,Vas Deferens,Volunteers},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\9DFAYM72\\Sharma et al. - 2019 - Safety & efficacy of an intravasal, one-time injec.pdf}
}

@article{SiContraceptionEtait2021,
  entrysubtype = {newspaper},
  title = {Et si la contraception était aussi l’affaire des hommes ?},
  date = {2021-11-13},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/m-perso/article/2021/11/13/parentologie-et-si-la-contraception-etait-aussi-l-affaire-des-hommes_6101909_4497916.html},
  urldate = {2023-05-22},
  abstract = {CHRONIQUE. Grand impensé de nos sociétés aux réflexes patriarcaux tenaces, la contraception masculine a pourtant été à l’ordre du jour dans les années 1980. Elle revient sur le devant de la scène, entre opération, slip chauffant et méthode hormonale.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\XQCBBP25\\parentologie-et-si-la-contraception-etait-aussi-l-affaire-des-hommes_6101909_4497916.html}
}

@article{soufirReversibleInhibitionSperm1983,
  title = {Reversible Inhibition of Sperm Production and Gonadotrophin Secretion in Men Following Combined Oral Medroxyprogesterone Acetate and Percutaneous Testosterone Treatment},
  author = {Soufir, Jean-Claude and Jouannet, Pierre and Marson, Jocelyne and Soumah, Arlette},
  date = {1983-04},
  journaltitle = {Acta Endocrinologica},
  volume = {102},
  number = {4},
  pages = {625--632},
  issn = {0804-4643, 1479-683X},
  doi = {10.1530/acta.0.1020625},
  url = {https://academic.oup.com/ejendo/article/102/4/625/6802583},
  urldate = {2023-05-20},
  abstract = {Six men requesting male contraception received a daily oral dose of 20 mg medroxyprogesterone acetate (MPA) in combination with 50 or 100 mg percutaneous testosterone for 1 year. From the third month the sperm concentration was {$<$} 106/ml for all the men at one time or another during treatment, and usually {$<$} 5 \textbackslash m=x\textbackslash{} 106/ml, with an average reduction of 95\% with respect to pre-treatment values. The sperm count returned to previous values 3\textbackslash p=n-\textbackslash 6months after cessation of the treatment. While FSH and LH secretion was inhibited throughout the treatment period, plasma testosterone levels were not reduced. Oestradiol levels were unaffected while dihydrotestosterone was elevated. The secretory activity of the prostate and seminal vesicles was not appreciably affected; seminal carnitine concentration was reduced during the treatment with a subsequent return to pretreatment values. No pregnancies occurred during treatment. There was no impairment of libido in the subjects, nor any incidence of gynaecomastia, or increase in average body weight. The only observed metabolic side-effect was a moderate increase in glycaemia. A synergistic action of MPA and testosterone is proposed to explain the inhibition of gonadotrophin secretion.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\A73GN6AY\\Soufir et al. - 1983 - Reversible inhibition of sperm production and gona.pdf}
}

@online{SterilisationViseeContraceptive,
  title = {Stérilisation à visée contraceptive},
  url = {https://www.ameli.fr/assure/sante/themes/contraception/sterilisation-contraceptive-homme-femme},
  urldate = {2023-05-01},
  abstract = {La stérilisation à visée contraceptive ne peut être pratiquée que chez une personne majeure (homme ou femme). C'est une méthode permanente et irréversible.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\9L3CVE25\\sterilisation-contraceptive-homme-femme.html}
}

@article{tcherdukianContraceptionMasculineQuelles2020,
  title = {Contraception masculine : quelles (r)évolutions ?},
  shorttitle = {Contraception masculine},
  author = {Tcherdukian, J. and Mieusset, R. and Soufir, J.-C. and Huygues, E. and Martin, T. and Karsenty, G. and Lechevalier, E. and Perrin, J.},
  date = {2020-12},
  journaltitle = {Progrès en Urologie - FMC},
  shortjournal = {Progrès en Urologie - FMC},
  volume = {30},
  number = {4},
  pages = {F105-F111},
  issn = {1761676X},
  doi = {10.1016/j.fpurol.2020.07.002},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S1761676X20300493},
  urldate = {2023-05-08},
  abstract = {Although the spectrum of women contraceptives includes 11 different methods, only 3 are commonly used by men: condoms, withdrawal, which has a high failure rate, as well as vasectomy, considered as an irreversible method. Over the past 40 years, numerous studies have been carried out to develop safe and effective hormonal and non-hormonal male contraceptives. Although their effectiveness has been proven, hormonal and thermal male contraception are still little used. The principles, protocols, effectiveness, reversibility and acceptability of these two methods are presented, as well as the practical elements for their prescription and monitoring.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\VA6SYP9Z\\Tcherdukian et al. - 2020 - Contraception masculine  quelles (r)évolutions .pdf}
}

@inreference{Testicule2023,
  title = {Testicule},
  booktitle = {Wikipédia},
  date = {2023-05-14T17:27:48Z},
  url = {https://fr.wikipedia.org/w/index.php?title=Testicule&oldid=204241514},
  urldate = {2023-05-17},
  abstract = {Les testicules (testes) sont les gonades mâles des animaux. Ils appartiennent à l'appareil reproducteur masculin, ce sont les homologues des ovaires. Ils ont une double fonction, plus ou moins exprimée selon les périodes de la vie :  spermatogenèse (production de spermatozoïdes) ; stéroïdogenèse (fonction hormonale, active in utero lors de la différenciation sexuelle, puis brièvement dans les premiers mois suivant la naissance, puis à partir de la puberté jusqu'à la fin de la vie).La majorité des vertébrés possèdent des testicules jumelés. Chez les oiseaux, les reptiles, les poissons et les amphibies, ils sont internes (testicules intra-abdominaux). Chez les premiers mammifères, ils sont également internes (caractère plésiomorphe), en position intra-abdominale (Afrothériens, Insectivores, Siréniens). Puis ils migrent lors de l'embryogenèse (descente des testicules, descensus testiculorum) et deviennent externes, dans une poche qui s'appelle le scrotum, phénomène apparu il y a 147 millions d'années chez les mammifères thériens. Chez quelques espèces de mammifères (xénarthres, mammifères marins tels que les cétacés), l'ascension secondaire des gonades explique leurs testicules internes en position intra-abdominale.},
  langid = {french},
  annotation = {Page Version ID: 204241514},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\3CZMSBYD\\Testicule.html}
}

@article{thirumalaiDimethandroloneUndecanoateNovel2020,
  title = {Dimethandrolone {{Undecanoate}}, a {{Novel}}, {{Nonaromatizable Androgen}}, {{Increases P1NP}} in {{Healthy Men Over}} 28 {{Days}}},
  author = {Thirumalai, Arthi and Yuen, Fiona and Amory, John K and Hoofnagle, Andrew N and Swerdloff, Ronald S and Liu, Peter Y and Long, Jill E and Blithe, Diana L and Wang, Christina and Page, Stephanie T},
  date = {2020-10-22},
  journaltitle = {The Journal of Clinical Endocrinology and Metabolism},
  shortjournal = {J Clin Endocrinol Metab},
  volume = {106},
  number = {1},
  eprint = {33090208},
  eprinttype = {pmid},
  pages = {e171-e181},
  issn = {0021-972X},
  doi = {10.1210/clinem/dgaa761},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765650/},
  urldate = {2023-05-13},
  abstract = {Context Dimethandrolone undecanoate (DMAU) is being developed as a male contraceptive. Daily oral administration of DMAU, a potent androgen that is not aromatized, markedly suppresses serum testosterone (T) and estradiol (E2) in healthy men. E2 deficiency can increase bone resorption in men. Objective This work aimed to assess changes in bone turnover markers with DMAU administration in a 28-day study. Design A randomized, double-blind, placebo-controlled study was conducted. Setting This study took place at 2 academic medical centers. Participants Healthy men, age 18 to50 years (n = 81), participated. Intervention Men received 0, 100, 200, or 400 mg of oral DMAU for 28 days. Serum C-terminal telopeptide of type I collagen (CTX; bone resorption marker) and procollagen type I amino-terminal propeptide (P1NP; bone formation marker) were measured on days 1 and 28. Main Outcome Measures Changes in bone turnover markers and serum hormones over the treatment period were measured. Results On day 28, median serum T and E2 were markedly suppressed in all treatment groups vs placebo (P {$<$} .001 for both). Percentage change (\%) in serum P1NP significantly differed across treatment groups (P = .007): Serum P1NP significantly increased in the 200 mg (5\%, interquartile range [IQR] –7\% to 27\%) and 400 mg (22\%, IQR –1\% to 40\%) groups relative to placebo (–8\%, IQR –20\% to 0\%). Change (\%) in serum CTX did not differ between groups (P = .09). Conclusions DMAU administration for 28 days to healthy men leads to marked suppression of serum T and E2, yet increases P1NP, a serum marker of bone formation. Longer-term studies of the potent androgen DMAU are warranted to determine its impact on bone health in men.},
  pmcid = {PMC7765650},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\8U96AES2\\Thirumalai et al. - 2020 - Dimethandrolone Undecanoate, a Novel, Nonaromatiza.pdf}
}

@online{ThomasBoulouInterview,
  title = {Thomas bouloù : l’interview – infos pratiques sur la contraception testiculaire thermique},
  shorttitle = {Thomas bouloù},
  url = {https://contraceptionthermique.noblogs.org/thomas-boulou-interview/},
  urldate = {2023-05-22},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\2MX39YIQ\\thomas-boulou-interview.html}
}

@online{TousMoyensContraception2023,
  title = {Tous Les Moyens de Contraception Dans Un Tableau Comparatif.},
  date = {2023-02-22},
  url = {https://questionsexualite.fr/choisir-sa-contraception/ma-contraception-et-moi/tableau-comparatif-pour-vous-guider-dans-votre-choix-de-contraception},
  urldate = {2023-02-22},
  keywords = {comparatif,feminin,masculin,officiel},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\BI8R8L96\\tableau-comparatif-pour-vous-guider-dans-votre-choix-de-contraception.html}
}

@video{tvtours-valdeloireContraceptionMasculineConnaissezvous22,
  entrysubtype = {video},
  title = {Contraception Masculine : Connaissez-Vous Le Slip Chauffant ?},
  shorttitle = {Contraception Masculine},
  editor = {{TV Tours-Val de Loire}},
  editortype = {director},
  date = {0022-12-15},
  url = {https://www.youtube.com/watch?v=5gyRef93jnM},
  urldate = {2023-06-05},
  abstract = {Aujourd'hui dans TILT, nous parlons de la contraception masculine ! Le CHRU de Tours a développé des consultations qui lui sont dédiées.  Pour regarder l'émission en replay : Partie 1 : https://www.dailymotion.com/video/x86... Partie 2 : https://www.dailymotion.com/video/x86... Partie 3 : https://www.dailymotion.com/video/x86... Emission diffusée le 15/12/22 TV Tours-Val de Loire, votre actu' en circuit-court Chaîne 30 de votre box internet et 37 de la TNT  Replay et streaming sur www.tvtours.fr Pour toute demande de reportage : contact@tvtours.fr}
}

@online{UTBMClassementEcoles,
  title = {UTBM - Classement des écoles d'ingénieurs 2023},
  url = {https://etudiant.lefigaro.fr/etudes/ecoles-ingenieurs/classement/universite-de-technologie-de-belfort-montbeliard/},
  urldate = {2023-05-25},
  abstract = {Découvrez le classement de UTBM dans notre classement 2023 des meilleurs écoles d'ingénieurs. Retrouvez ses points forts, les salaires à la sortie, les frais de scolarité...},
  langid = {french},
  organization = {{Le Figaro Etudiant}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\EBQQHHIL\\universite-de-technologie-de-belfort-montbeliard.html}
}

@article{vanwerschAttitudesMaleContraceptive2012,
  title = {Attitudes towards the Male Contraceptive Pill: Psychosocial and Cultural Explanations for Delaying a Marketable Product},
  shorttitle = {Attitudes towards the Male Contraceptive Pill},
  author = {Van Wersch, A. and Eberhardt, J. and Stringer, F.},
  date = {2012-09},
  journaltitle = {Basic and Clinical Andrology},
  shortjournal = {Basic Clin. Androl.},
  volume = {22},
  number = {3},
  pages = {171--179},
  issn = {2051-4190},
  doi = {10.1007/s12610-012-0185-4},
  url = {https://bacandrology.biomedcentral.com/articles/10.1007/s12610-012-0185-4},
  urldate = {2023-05-08},
  abstract = {Even though years of research on the male contraceptive pill have been conducted, a marketable product is still absent from the arsenal of male and female products of contraception. In this paper, the following psychosocial and cultural factors have been elicited from the literature in order to reveal explanations for this delay: acceptability, trust, fear of side-effects, perceptions of contraceptive responsibility and fear of losing connotations of masculinity. Regardless of cultural variation, overall there seems to be a positive attitude towards the acceptability of male contraceptive for both males and females, especially males in stable relationships. Some indication shows that the media have played an important role in distorting the results of research regarding male and female trust. Ongoing and future researches into several projects on psychosocial and cultural factors are described.},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\RTKW4IJ4\\Van Wersch et al. - 2012 - Attitudes towards the male contraceptive pill psy.pdf}
}

@online{VasalgelMaleContraceptive,
  title = {Vasalgel {{Male Contraceptive}}},
  url = {https://www.parsemus.org/humanhealth/male-contraceptive-research/vasalgel-male-contraceptive/},
  urldate = {2023-05-19},
  abstract = {Vasalgel is a male contraceptive launched by Parsemus Foundation to fill the need for a non-hormonal, long-acting, reversible male method.},
  langid = {american},
  organization = {{Parsemus Foundation}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\K28BJK56\\vasalgel-male-contraceptive.html}
}

@online{VasectomieEstelleReversible,
  title = {La vasectomie est-elle réversible, comme le dit la série «The Office» ?},
  url = {https://www.liberation.fr/checknews/2019/07/05/la-vasectomie-est-elle-reversible-comme-le-dit-la-serie-the-office_1737961/},
  urldate = {2023-05-01},
  abstract = {La vasectomie est une méthode considérée comme définitive, car la réussite de l'opération inverse n'est pas garantie.},
  langid = {french},
  organization = {{Libération}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\NE8CR5FD\\la-vasectomie-est-elle-reversible-comme-le-dit-la-serie-the-office_1737961.html}
}

@online{VasectomieToutSavoir2017,
  title = {La vasectomie : tout savoir sur la stérilisation masculine},
  shorttitle = {La vasectomie},
  date = {2017-09-24},
  url = {https://www.passeportsante.net/fr/Maux/examens-medicaux-operations/Fiche.aspx?doc=vasectomie},
  urldate = {2023-05-01},
  abstract = {La vasectomie est une technique de stérilisation masculine considérée comme définitive. Elle consiste empêcher les spermatozoïdes d’être incorporés à l’éjaculat.},
  langid = {french},
  organization = {{https://www.passeportsante.net/}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\E5XVXINI\\Fiche.html}
}

@article{VersPiluleContraceptive2012,
  entrysubtype = {newspaper},
  title = {Vers une pilule contraceptive masculine},
  date = {2012-08-16},
  journaltitle = {Le Monde.fr},
  url = {https://www.lemonde.fr/sciences/article/2012/08/16/vers-une-pilule-contraceptive-masculine_1746855_1650684.html},
  urldate = {2023-03-06},
  abstract = {Un nouveau front s'est ouvert dans la quête d'un contraceptif masculin : grâce à une petite molécule, la fabrication de spermatozoïdes a pu être bloquée de façon spécifique et réversible chez des souris.},
  langid = {french},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\DJEBP4LN\\vers-une-pilule-contraceptive-masculine_1746855_1650684.html}
}

@article{waitesDevelopmentMethodsMale2003,
  title = {Development of Methods of Male Contraception: Impact of the {{World Health Organization Task Force}}},
  shorttitle = {Development of Methods of Male Contraception},
  author = {Waites, Geoffrey M.H.},
  date = {2003-07},
  journaltitle = {Fertility and Sterility},
  shortjournal = {Fertility and Sterility},
  volume = {80},
  number = {1},
  pages = {1--15},
  issn = {00150282},
  doi = {10.1016/S0015-0282(03)00577-6},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S0015028203005776},
  urldate = {2023-02-28},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\KCE2L8YR\\Waites - 2003 - Development of methods of male contraception impa.pdf}
}

@article{wallachRoleTemperatureRegulation1988,
  title = {Role of Temperature in Regulation of Spermatogenesis and the Use of Heating as a Method for Contraception},
  author = {Wallach, Edward E. and Kandeel, Fouad R. and Swerdloff, Ronald S.},
  date = {1988-01-01},
  journaltitle = {Fertility and Sterility},
  shortjournal = {Fertility and Sterility},
  volume = {49},
  number = {1},
  pages = {1--23},
  issn = {0015-0282},
  doi = {10.1016/S0015-0282(16)59640-X},
  url = {https://www.sciencedirect.com/science/article/pii/S001502821659640X},
  urldate = {2023-05-17},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\EGU7PYRT\\Wallach et al. - 1988 - Role of temperature in regulation of spermatogenes.pdf;C\:\\Users\\esteb\\Zotero\\storage\\ZBCWGAAW\\S001502821659640X.html}
}

@article{wangBETBromodomainInhibitor2022,
  title = {{{BET}} Bromodomain Inhibitor {{JQ1}} Regulates Spermatid Development by Changing Chromatin Conformation in Mouse Spermatogenesis},
  author = {Wang, Xiaorong and Sang, Mengmeng and Gong, Shengnan and Chen, Zhichuan and Zhao, Xi and Wang, Guishuan and Li, Zhiran and Huang, Yingying and Chen, Shitao and Xie, Gangcai and Duan, Enkui and Sun, Fei},
  date = {2022-07},
  journaltitle = {Genes \& Diseases},
  shortjournal = {Genes \& Diseases},
  volume = {9},
  number = {4},
  pages = {1062--1073},
  issn = {23523042},
  doi = {10.1016/j.gendis.2020.12.012},
  url = {https://linkinghub.elsevier.com/retrieve/pii/S2352304221000076},
  urldate = {2023-03-06},
  langid = {english},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\GN4M6TIJ\\Wang et al. - 2022 - BET bromodomain inhibitor JQ1 regulates spermatid .pdf}
}

@online{WikiwandHypothalamicPituitary,
  title = {Wikiwand - {{Hypothalamic}}–Pituitary–Gonadal Axis},
  url = {https://wikiwand.com/en/Hypothalamic–pituitary–gonadal_axis},
  urldate = {2023-05-08},
  abstract = {The hypothalamic–pituitary–gonadal axis refers to the hypothalamus, pituitary gland, and gonadal glands as if these individual endocrine glands were a single entity. Because these glands often act in concert, physiologists and endocrinologists find it convenient and descriptive to speak of them as a single system. The HPG axis plays a critical part in the development and regulation of a number of the body's systems, such as the reproductive and immune systems. Fluctuations in this axis cause changes in the hormones produced by each gland and have various local and systemic effects on the body. The axis controls development, reproduction, and aging in animals. Gonadotropin-releasing hormone is secreted from the hypothalamus by GnRH-expressing neurons. The anterior portion of the pituitary gland produces luteinizing hormone and follicle-stimulating hormone , and the gonads produce estrogen and testosterone.},
  organization = {{Wikiwand}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\U33NAL4V\\Hypothalamic–pituitary–gonadal_axis.html}
}

@online{WikiwandPreservatif1920,
  title = {Wikiwand - {{Préservatif}}},
  date = {1920-07-31},
  url = {https://wikiwand.com/fr/Préservatif},
  urldate = {2023-05-01},
  abstract = {Le préservatif ou condom est un étui mince et souple, imperméable au sang, au sperme ainsi qu'aux sécrétions vaginales et péniennes, fabriqué en latex ou en polyuréthane. Il en existe deux types : le préservatif externe et le préservatif interne . Le premier est aussi nommé plus familièrement « capote » en français européen. Le préservatif s'avère être très efficace pour empêcher la transmission des infections sexuellement transmissibles par les sécrétions vaginales, péniennes et le sperme mais n'offre pas de protection face aux IST présentes sur les surfaces cutanées de la zone génitale. Ainsi le préservatif, correctement utilisé lors d'une relation sexuelle avec pénétration, est le seul contraceptif qui protège de la transmission du VIH et de l'hépatite B. Il ne constitue en revanche pas une protection efficace contre d'autres IST occasionnant un nombre important de décès, comme la syphilis .},
  organization = {{Wikiwand}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\AI3AI3PQ\\Préservatif.html}
}

@online{WikiwandRisug2005,
  title = {Wikiwand - {{Risug}}},
  date = {2005-07},
  url = {https://wikiwand.com/fr/Risug},
  urldate = {2023-05-19},
  abstract = {Le  RISUG , anciennement dénommé SMA,  est le nom de développement d'un contraceptif masculin développé à l'Institut indien de technologie de Kharagpur en Inde par le Dr Sujoy K. Guha. Il est actuellement en phase III des essais cliniques . Ce dernier a été breveté en Inde, en Chine, au Bangladesh, aux États-Unis et au Canada.},
  organization = {{Wikiwand}},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\VF3J4F8U\\Risug.html}
}

@online{ZoteroYourPersonal,
  title = {Zotero | {{Your}} Personal Research Assistant},
  url = {https://www.zotero.org/start},
  urldate = {2023-02-22},
  file = {C\:\\Users\\esteb\\Zotero\\storage\\LSCHTE7Z\\start.html}
}
